Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Molecular and Structural Perspective on Bluetongue Virus Entry and Assembly.

Pathogens (Basel, Switzerland)·2026
Same author

Visualization of Bluetongue Virus RNA Segment Networks in Infected Cells: Multipartite Genomic RNA Assortment Is Independent of Viral Proteins NS2 and VP6.

Viruses·2026
Same author

Insect-borne non-enveloped bluetongue virus utilizes discrete small vesicles for non-lytic release and cell-to-cell transmission.

PLoS pathogens·2025
Same author

Visualization and tracking of tubule-derived, fluorescent-labeled NS1 as a marker of bluetongue virus in living cells.

Journal of virology·2025
Same author

Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation.

International journal of molecular sciences·2025
Same author

Identification of immunogenic and cross-reactive chikungunya virus epitopes for CD4<sup>+</sup> T cells in chronic chikungunya disease.

Nature communications·2025

Related Experiment Video

Updated: Aug 24, 2025

Rescue and Characterization of Recombinant Virus from a New World Zika Virus Infectious Clone
07:35

Rescue and Characterization of Recombinant Virus from a New World Zika Virus Infectious Clone

Published on: June 7, 2017

9.8K

Enhanced Zika virus-like particle development using Baculovirus spp. constructs.

Alexander Malogolovkin1, Andrew Davies1, Sherif Abouelhadid1

  • 1Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.

Journal of Medical Virology
|October 22, 2022
PubMed
Summary

Researchers developed Zika virus-like particles (VLPs) to study virus-antibody interactions. A novel construct enhanced VLP production, offering potential for improved diagnostics and vaccine development against Zika virus (ZIKV).

Keywords:
BaculovirusZika virusenvelope proteinflavivirusviral-like particle

More Related Videos

Rescue of Recombinant Zika Virus from a Bacterial Artificial Chromosome cDNA Clone
08:10

Rescue of Recombinant Zika Virus from a Bacterial Artificial Chromosome cDNA Clone

Published on: June 24, 2019

26.9K
Production and Purification of Baculovirus for Gene Therapy Application
06:11

Production and Purification of Baculovirus for Gene Therapy Application

Published on: April 9, 2018

15.2K

Related Experiment Videos

Last Updated: Aug 24, 2025

Rescue and Characterization of Recombinant Virus from a New World Zika Virus Infectious Clone
07:35

Rescue and Characterization of Recombinant Virus from a New World Zika Virus Infectious Clone

Published on: June 7, 2017

9.8K
Rescue of Recombinant Zika Virus from a Bacterial Artificial Chromosome cDNA Clone
08:10

Rescue of Recombinant Zika Virus from a Bacterial Artificial Chromosome cDNA Clone

Published on: June 24, 2019

26.9K
Production and Purification of Baculovirus for Gene Therapy Application
06:11

Production and Purification of Baculovirus for Gene Therapy Application

Published on: April 9, 2018

15.2K

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • Zika virus (ZIKV) poses a significant pandemic threat with no current vaccine or treatment.
  • Understanding ZIKV-antibody interactions is crucial for developing effective countermeasures.
  • Recombinant virus-like particles (VLPs) are valuable tools for studying viral structure and immune responses.

Purpose of the Study:

  • To construct and characterize novel baculovirus-derived ZIKV-like particles (VLPs).
  • To investigate ZIKV-antibody interactions using these engineered VLPs.
  • To optimize VLP production for enhanced diagnostic and immunogenic assessments.

Main Methods:

  • Engineered VLPs incorporating full-length ZIKV capsid (C), pre-membrane (prM), and envelope (E) proteins.
  • Utilized baculovirus expression systems in insect (Sf9) and mammalian (HEK293T) cells.
  • Employed transmission electron microscopy for morphological analysis and assessed glycosylation impacts on antibody binding.

Main Results:

  • Successfully produced ZIKV-like particles (VLPs) with typical virion morphology in both insect and mammalian cells.
  • Demonstrated the importance of E glycoprotein glycosylation in ZIKV-antibody interactions.
  • Identified a superior VLP construct (furin cleavage sequence, leader/signal sequences, single promoter) yielding higher titers and protein concentrations.

Conclusions:

  • The developed Zika VLPs are suitable for studying ZIKV-antibody interactions and viral glycoprotein importance.
  • The optimized VLP construct shows promise for advanced diagnostic assays (ELISA, neutralization) and immunogenic evaluations.
  • This work potentially paves the way for ZIKV vaccine development and improved diagnostic tools.